From the June 2017 issue of HealthCare Business News magazine
The radiopharmaceutical industry is full of passionate individuals focused on improving patient care. I believe that through continued investment in research through public and private organizations, along with government grants, we’ll continue to see new developments that will grow our industry. The IDEAS study is a great example of financial investment from both industry and government to advance diagnosis and treatment.
HCB News: What other dynamics are impacting the radiopharmaceutical industry?
TO: We continue to be optimistic about therapeutic radiopharmaceuticals in the drug development pipeline. The unique aspects of radioisotopes, combined with new pharmaceuticals, make this a cutting-edge area that will truly improve patient care.
Ad Statistics
Times Displayed: 2147
Times Visited: 10 Fast-moving cardiac structures have a big impact on imaging. Fujifilm’s SCENARIA View premium performance CT brings solutions to address motion in Coronary CTA while delivering unique dose saving and workflow increasing benefits.
We continue to experience industry changes of acquisitions and divestitures. This year Cardinal Health acquired North American rights to Lymphoseek® from Navidea. We are thrilled with how the integration is moving, and are driven by the goal of providing continued access of the product to our hospital and clinic customers who have found great value in using Lymphoseek®.
HCB News: What do you anticipate from President Trump’s administration and shifting political landscape?
TO: Our fundamental strategy at Cardinal Health remains consistent. We’ll continue to operate with patient and employee safety as a top priority, and remain focused on value-based care, controlling costs and emphasizing disease prevention and improved patient outcomes.
Back to HCB News
